Breaking News: FDA Approves NMN as a Dietary Supplement, Setting a Unified Signal for Global Markets

On September 29, the global healthy aging industry received groundbreaking news: the U.S. Food and Drug Administration (FDA) officially announced its decision to recognize NMN (β-nicotinamide mononucleotide) as a lawful dietary supplement for the U.S. market^[1]. This NMN FDA approval removes the largest regulatory barrier in the United States, signaling that consumers will soon have broader and more reliable access to the benefits of this promising longevity ingredient. Moreover, the FDA’s decision is expected to accelerate NMN’s acceptance across Europe and other international markets.

As a pioneer in the anti-aging raw materials sector, EffePharm has consistently committed to advancing longevity science with rigorously validated ingredients. Its flagship brand, UTHEVER® NMN, stands as the first branded NMN ingredient worldwide to complete large-scale human studies. For EffePharm, this milestone is not only an industry breakthrough but also a meaningful step toward making healthy aging more accessible and transparent.

01

Dispute Resolved: NMN Proven Safe, Legal Questions at the Core

The recent scandal around NMN was not that it was unsafe. Over the years, scientific evidence has all been in favor of NMN maintaining its safety. However, the dispute was due to a legal issue in the U.S. Federal Food, Drug, and Cosmetic Act, namely the “drug preclusion clause.”

At the beginning of the year, the situation looked very vague. The FDA in July delayed its reaction, which made the industry worried. Nevertheless, the course of the drafts has changed as the scientific data and the practical examples have become the main basis for the decision. The FDA-approved NMN statement indicates that the agency is taking a more practical and science-led approach in the regulation of new dietary ingredients.

The verdict also deals with issues raised by the public, for instance: Is NMN legal in the USA? The response is that NMN is now a dietary supplement legally authorized, thus, at the time of writing, the point at which the acceptance of the international community is moving beyond is being established.

02

Science and Compliance: UTHEVER® NMN Leading the Way

Throughout this regulatory journey, UTHEVER® NMN has consistently demonstrated scientific credibility and proactive compliance.

Science as the foundation:
UTHEVER® NMN is the first NMN ingredient to complete a large-scale human trial, providing high-level data to support its efficacy and safety. This achievement underscores EffePharm’s belief that only science-backed ingredients can stand the test of time in the global market of top NMN supplements.

Compliance as responsibility:
EffePharm has always been dedicated to complying with the highest regulatory standards. In fact, the company went ahead to submit a New Dietary Ingredient (NDI) application to the FDA, thereby being accountable to both consumers and business partners, even before the FDA announcement.

Meanwhile, EffePharm has made great strides in Europe as well. By being the first brand to pass the public consultation stage of the European Food Safety Authority (EFSA) process for NMN Novel Food, EffePharm gained a strong presence in one of the most stringent regulatory environments in the world. This dual strategy—NDI in the U.S. and Novel Food in Europe—gives EffePharm the advantage of being a leader in the global NMN supplement FDA landscape, a trusted one.

03

Outlook: A New Chapter for Healthy Aging

The FDA’s decision to remove the FDA NMN supplement ban 2025 update barrier represents more than just a U.S. policy shift. It establishes an international benchmark for harmonizing regulations in emerging longevity ingredients. For Europe and other regions, the FDA approval provides both scientific validation and regulatory reference.

Moving forward, this milestone is expected to drive greater confidence in the NMN industry, fueling growth in categories such as bulk NMN supply and finished consumer products. As consumer demand for reliable and effective solutions grows, EffePharm’s forward-looking compliance and scientific strength ensure it will remain a partner of choice in the development of top NMN supplements.

EffePharm will remain committed to the core values of innovation, thorough testing, and adherence to international standards, providing the world with accessible, effective, and safe healthcare solutions. The company plans to accelerate the adoption of NMN through close coordination with partners worldwide, leading the entire healthy aging sector to a new level of quality standards.

About EffePharm:

Effepharm is a biotechnology company dedicated to delivering scientifically supported functional ingredients to consumers. We continuously identify market gaps and address unmet needs in life and health. As an expert in multiple single-ingredient categories, we possess strong capabilities in product innovation, industry-leading iterations, and resource integration. Our business spans across human nutrition, beauty and personal care, as well as animal nutrition, creating valuable brands for our partners and providing safe, effective, and sustainable products for consumers.

References:
[1] Amid Pressure From NPA, FDA Declares NMN Lawful In Dietary Supplements | Natural Products Association. (2025, September 29). Natural Products Association. https://www.npanational.org/news/amid-pressure-from-npa-fda-declares-nmn-lawful-in-dietary-supplements/